NVIDIA and Eli Lilly Launch Up to $1B AI Co-Innovation Lab for Drug Discovery
On January 12, 2026, at the J.P. Morgan Healthcare Conference, NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab with a joint investment of up to $1 billion over five years. The Bay Area lab will co-locate Lilly biologists with NVIDIA AI engineers on BioNeMo and Vera Rubin infrastructure for closed-loop wet-lab and dry-lab discovery.
TLDR
NVIDIA and Eli Lilly on January 12, 2026 announced an AI co-innovation lab dedicated to drug discovery and development, with the companies jointly investing up to $1 billion over five years in infrastructure and research. Announced at the J.P. Morgan Healthcare Conference, the Bay Area / South San Francisco lab pairs Lilly domain experts with NVIDIA model builders on BioNeMo and Vera Rubin-class systems for continuous, AI-assisted experimentation.
Deal and lab design
From NVIDIA and Lilly primary releases (January 12, 2026):
- Investment: Up to $1 billion over five years (joint infrastructure, workforce, and compute—not a single one-time equity check alone).
- Mission: Apply AI to enduring pharma challenges—accelerated discovery, better clinical development models, and eventually robotics/physical AI for discovery and production.
- Location: San Francisco Bay Area lab co-locating Lilly scientists (biology, medicine) with NVIDIA AI engineers.
- Operating model: “Scientist in the loop” / closed-loop connection between agentic wet labs and computational dry labs, aiming for 24/7 AI-assisted experimentation.
- Stack: Built on NVIDIA BioNeMo and Vera Rubin architecture for life-sciences AI infrastructure.
- Timing: Work to begin early 2026; framed as first-of-its-kind pharma–chip co-innovation lab at this scale.
Why this story matters
The biggest AI capex wave is no longer only hyperscaler chatbots—it is silicon married to wet-lab biology. A $1B NVIDIA–Lilly lab is a blueprint other pharmas will copy: put domain experts next to GPU builders, close the loop between experiment and model, and treat drug discovery as an engineering system.
Sources
- NVIDIA investor newsroom: “NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI” (January 12, 2026). Primary.
- Eli Lilly / Fierce Biotech / Bloomberg contemporaneous JPM coverage (January 12, 2026).
Featured Image Alt Text
NVIDIA and Eli Lilly logos over a wet-lab bench connected to GPU clusters with BioNeMo branding.
Tags
NVIDIA, Eli Lilly, Drug Discovery, BioNeMo, Life Sciences, JPM Healthcare, Infrastructure